; and (B) the Director of the Center for Biologics Evaluation and Research shall meet quarterly with the Department of Defense to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that are the highest priorities to the Department of Defense (which may include freeze dried plasma products and platelet alternatives), unless the Secretary of Defense determines that any such meetings are not necessary. (4) Medical product In this subsection, the term medical product means a drug (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 )), a device (as defined in such section 201), or a biological product (as defined in section 351 of the Public Health Service Act ( 42 U.S.C. 262 )). (c) Repeal Effective as of the enactment of the National Defense Authorization Act for Fiscal Year 2018, subsection (d) of section 1107a of title 10, United States Code, as added by section 716 of the National Defense Authorization Act for Fiscal Year 2018, is repealed.